Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.

    Cancer Cell 2017 09;32(3):392
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1016/j.ccell.2017.08.009DOI ListingPossible

    Similar Publications

    Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.
    Cancer Cell 2017 07;32(1):6-8
    University of California, San Francisco, CA, USA. Electronic address:
    Two papers published recently in the New England Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor, in the early treatment of metastatic prostate cancer. In addition to establishing a new standard of care, these two articles pose a number of important questions for future investigation. Read More
    Redefining hormone sensitive disease in advanced prostate cancer.
    Adv Urol 2012 25;2012:978531. Epub 2012 Feb 25.
    Division of Medical Oncology, University of Colorado Denver School of Medicine, 12801 E. 17th Avenue, Room L18-8117, Aurora, CO 80045, USA.
    Prostate cancer is the most common cancer among men in the United States. For decades, the cornerstone of medical treatment for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation Therapy (ADT). The development of hormone-resistant prostate cancer (now termed castration-resistant prostate cancer:CRPC) remains the key roadblock in successful long-term management of prostate cancer. Read More
    The timing of hormone therapy for men with asymptomatic advanced prostate cancer.
    Urol Oncol 2003 Jul-Aug;21(4):245-54
    Department of Urology, University of Rochester, Rochester, NY 14642, USA.
    The most appropriate time to introduce hormonal therapy for patients with advanced prostate cancer is a contentious issue. Recent prospective studies comparing immediate and deferred hormonal therapy (medical or surgical castration) on survival outcome are reviewed with the aim of redefining the most appropriate time to initiate hormonal therapy for individual patients. The evidence supports the use of immediate hormonal therapy in previously untreated patients with advanced disease (M1) and also the use of adjuvant hormonal therapy after radical prostatectomy and lymphadenectomy for node-positive (but clinically localized) disease. Read More
    The STAMPEDE trial: paradigm-changing data through innovative trial design.
    Transl Cancer Res 2016 Sep;5(3 Suppl):S485-S490
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
    Despite the numerous regulatory approvals for prostate cancer, metastatic prostate cancer remains a huge burden for men worldwide. In an exciting development, James. recently published data from the Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: a multi-stage multi-arm randomised control trial (STAMPEDE). Read More